(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 337.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Oculis Holding Ag's revenue in 2025 is $762,222.On average, 3 Wall Street analysts forecast OCS's revenue for 2025 to be $38,990,525, with the lowest OCS revenue forecast at $29,690,433, and the highest OCS revenue forecast at $44,535,650. On average, 3 Wall Street analysts forecast OCS's revenue for 2026 to be $1,272,584,369, with the lowest OCS revenue forecast at $354,102,080, and the highest OCS revenue forecast at $2,445,531,136.
In 2027, OCS is forecast to generate $2,859,014,083 in revenue, with the lowest revenue forecast at $2,555,560,389 and the highest revenue forecast at $3,162,467,777.